Insider buys into strength as the Elanco stock price has outperformed the S&P 500 over the last 12 months.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Elanco’s results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that “Zenrelia was the largest contributor to second quarter total Elanco growth,” with broad-based gains from innovative treatments and share gains in co

Zenrelia and Credelio Quattro drove blockbuster growth and margin expansion.

In early August 2026, Elanco Animal Health reported Q2 sales of US$1,368 million and net income of US$54 million, alongside an FDA Emergency Use Authorization for its CLiK Extra screwworm-prevention spray across multiple livestock and wildlife species. The combination of stronger earnings, raised full-year revenue guidance to US$5,090 million–US$5,140 million, and expanded screwworm-related offerings positions Elanco as a key player in responding to a renewed New World screwworm...

Elanco Animal Health (ELAN) is back in focus after receiving U.S. Food and Drug Administration Emergency Use Authorization for CLiK Extra wound spray, a product aimed at preventing New World screwworm infestations across a wide range of livestock and wildlife. See our latest analysis for Elanco Animal Health. Despite the fresh Emergency Use Authorization news, Elanco Animal Health’s recent share price momentum has cooled, with the stock down 16.12% over seven days and 10.88% over 30 days...

Elanco Animal Health (NYSE:ELAN) reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth. Chief Executive Officer Jeff Simmons said

Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent surge in tick bites and consumer spending on pet health products.

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Elanco Animal Health Inc (ELAN) delivers robust Q2 2026 results, fueled by blockbuster products Zenrelia and Credelio Quattro, leading to improved profitability and a strengthened balance sheet.

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health (ELAN) delivered earnings and revenue surprises of +25.93% and +4.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.2% year on year to $1.37 billion. Guidance for next quarter’s revenue was better than expected at $1.21 billion at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.34 per share was 26.5% above analysts’ consensus estimates.

Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories

In July 2026, Elanco Animal Health reported peer-reviewed data showing its Credelio Quattro chewable tablets killed black-legged and lone star ticks faster and with more sustained efficacy over 28 days than competing products Simparica Trio and NexGard Plus, while also carrying an FDA-approved claim for Lyme disease prevention in dogs. The unique combination of rapid tick kill within 8 to 12 hours and maintained performance through Day 28 could strengthen Credelio Quattro’s competitive...

Elanco Animal Health stock has delivered a strong 107.8% return over the past three years, yet its current share price of US$24.91 still screens as undervalued when set against an intrinsic value estimate based on a Discounted Cash Flow (DCF) model and broader valuation checks. The 107.8% three year return points to a stock that has already rewarded patient holders, so the main question now is how much upside, if any, remains in the current valuation. Expectations that Elanco Animal Health...

Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.